# Phenylalanine accumulation in PAH deficiency: research update

Dated 5 October 2026. Local prepublication addendum; archived grade unchanged.

Early exposure and early treatment support phenylalanine-related developmental injury in PKU. Adult challenge experiments, brain transport and discordant untreated outcomes refine vulnerability and reversibility; biochemical lowering and neurocognitive recovery remain separate endpoints.

## Research timeline

Electronic year is used where recorded; issue year is retained in each source card. The chronology is selected, not exhaustive, and does not establish priority or causation.

| Year | Primary study | Design and finding | Inference limit |
|---|---|---|---|
| 1953 | [Influence of phenylalanine intake on phenylketonuria.](https://pubmed.ncbi.nlm.nih.gov/13098090/) | Historical dietary report. An early report examined phenylalanine intake in PKU. | Metadata-only historical anchor: outcome details were not independently re-examined in this update. |
| 1974 | [Natural history of phenylketonuria and influence of early treatment.](https://pubmed.ncbi.nlm.nih.gov/4140266/) | Affected-sibling comparison. Earlier treatment was associated with better intellectual outcomes. | Nonrandomized developmental treatment comparison; family and timing factors require attention. |
| 1998 | [Blood-brain barrier phenylalanine transport and individual vulnerability in phenylketonuria.](https://pubmed.ncbi.nlm.nih.gov/9809507/) | Brain spectroscopy and phenylalanine challenge. Brain transport varied among patients with different clinical vulnerability. | Small selected sample does not explain all preserved untreated cognition. |
| 1999 | [Large neutral amino acids block phenylalanine transport into brain tissue in patients with phenylketonuria.](https://pubmed.ncbi.nlm.nih.gov/10207169/) | Human LNAA/phenylalanine challenge. Other large neutral amino acids blocked brain phenylalanine influx and EEG slowing. | Acute transport and EEG effects do not establish long-term cognitive recovery. |
| 2007 | [Efficacy of sapropterin dihydrochloride (tetrahydrobiopterin, 6R-BH4) for reduction of phenylalanine concentration in patients with phenylketonuria: a phase III randomised placebo-controlled study.](https://pubmed.ncbi.nlm.nih.gov/17693179/) | Sapropterin randomized trial. Responsive patients had lower blood phenylalanine on treatment. | Blood lowering is not itself a hard neurocognitive outcome. |
| 2010 | [High phenylalanine levels directly affect mood and sustained attention in adults with phenylketonuria: a randomised, double-blind, placebo-controlled, crossover trial.](https://pubmed.ncbi.nlm.nih.gov/21153445/) | Adult randomized crossover challenge. Higher phenylalanine impaired sustained attention and mood in the tested adults. | Short challenge in early-treated adults does not measure irreversible childhood injury. |
| 2017 | [Blood phenylalanine reduction corrects CNS dopamine and serotonin deficiencies and partially improves behavioral performance in adult phenylketonuric mice.](https://pubmed.ncbi.nlm.nih.gov/29331172/) | Adult phenylketonuric-mouse intervention. Blood lowering corrected monoamine deficits and partly improved behaviour. | Adult biochemical rescue did not reverse all developmental cognitive deficits. |
| 2018 | [Pegvaliase for the treatment of phenylketonuria: A pivotal, double-blind randomized discontinuation Phase 3 clinical trial.](https://pubmed.ncbi.nlm.nih.gov/29628378/) | Pegvaliase randomized discontinuation. Continuation maintained lower blood phenylalanine than discontinuation. | An enriched withdrawal design tests maintenance, not untreated developmental causation. |
| 2024 | [Cognition after a 4-week high phenylalanine intake in adults with phenylketonuria - a randomized controlled trial.](https://pubmed.ncbi.nlm.nih.gov/38569786/) | Four-week adult randomized challenge. Working-memory accuracy met the noninferiority criterion, while sustained attention differed. | Domain-specific and short-term outcomes do not justify a general claim that high phenylalanine is harmless. |
| 2026 | [Two adult sisters with untreated phenylketonuria: Strikingly discordant clinical phenotype.](https://pubmed.ncbi.nlm.nih.gov/41853686/) | Untreated adult-sister case comparison. Sisters had strikingly different cognitive outcomes despite similar tested biochemical/genetic features. | A rare discordant pair identifies an unresolved modifier rather than reversing population-level causation. |

## Research gaps

### G1: What determines individual brain exposure and vulnerability?

Evidence anchors: [P9809507](https://pubmed.ncbi.nlm.nih.gov/9809507/), [P10207169](https://pubmed.ncbi.nlm.nih.gov/10207169/), [P41853686](https://pubmed.ncbi.nlm.nih.gov/41853686/).

Competing explanation: Blood phenylalanine may imperfectly reflect transport, protective modifiers or prior developmental exposure.

Discriminating test and controls: Longitudinal brain spectroscopy, genotype and exposure histories in prospectively identified discordant cases; matched ascertainment and independent replication.

### G2: Which adult domains change reversibly over which time scale?

Evidence anchors: [P21153445](https://pubmed.ncbi.nlm.nih.gov/21153445/), [P38569786](https://pubmed.ncbi.nlm.nih.gov/38569786/), [P29331172](https://pubmed.ncbi.nlm.nih.gov/29331172/).

Competing explanation: Attention, mood and working memory may differ in sensitivity and recovery.

Discriminating test and controls: Longer controlled exposure/reduction studies with prespecified domains, washout and repeated brain measures; distinguish early-treated adults from developmental injury.

### G3: Which mediator carries developmental versus adult effects?

Evidence anchors: [P10207169](https://pubmed.ncbi.nlm.nih.gov/10207169/), [P29331172](https://pubmed.ncbi.nlm.nih.gov/29331172/), [P4140266](https://pubmed.ncbi.nlm.nih.gov/4140266/).

Competing explanation: Transport competition, monoamine inhibition and developmental structural effects may have different roles.

Discriminating test and controls: Age-stratified model blockade/rescue and human mediator measurement; require outcomes beyond blood phenylalanine and avoid attributing every effect to one pathway.

### G4: Do newer lowering strategies improve durable neurocognitive outcomes?

Evidence anchors: [P17693179](https://pubmed.ncbi.nlm.nih.gov/17693179/), [P29628378](https://pubmed.ncbi.nlm.nih.gov/29628378/), [P21153445](https://pubmed.ncbi.nlm.nih.gov/21153445/).

Competing explanation: A biochemical response may leave previous damage or adherence-related fluctuations unchanged.

Discriminating test and controls: Prospective comparative follow-up with cognition, function, exposure variability and adverse events; separate responder-enriched maintenance from initiation trials.

## Methods and access

Case-specific Consensus records assisted gap discovery, chronology and targeted paper questions. Shared template wording about an amyloid-specific Deep follow-up is not evidence of a Deep run for this topic; the dated source records establish the actual use and access limits. Primary identifiers, selected abstract passages, correction notices and available primary-body passages were cross-checked. Generated absence cells, duplicate milestones and unsupported access claims were rejected.

This focused addendum does not establish 50–70 complete primary Methods/Results examinations per review. Baseline reading receipts and scores retain their original scope.

Checked timeline sources: 10; selected full-text checks: 1; abstract-excerpt checks: 8; metadata-only historical anchors: 1. Complete papers examined in this update: 0.

Historical scorecards declare schema 5.4. This enrichment uses HSEF v5.3 causal distinctions without retrospectively relabelling or rescoring those files.

Targeted paper-check scope: Results: washout was at least four weeks and phenylalanine approached baseline before the second period. Adult challenge outcomes do not test fixed childhood injury.